# Brad (Neuralink participant) **Entity class:** Technology, method, or technical system **Type:** Person **Collection:** [[collections/Neurotech|Neurotech]] **Primary source:** [[articles/2026 Annual Report on Brain-Computer Interfaces|2026 Annual Report on Brain-Computer Interfaces]] ## Definition Brad is identified in the source as a Neuralink participant and the first participant with ALS in the trial described there. ## Relationships [[wiki/Brad (Neuralink participant)|Brad]] is related to [[wiki/Neuralink|Neuralink]], [[wiki/N1 Link|N1 Link]], and [[wiki/Amyotrophic Lateral Sclerosis|amyotrophic lateral sclerosis]]. <!-- BEGIN HUMANIZED RELATIONSHIPS 2026-09-11 --> This entry's documented connections are expressed in its definition and related-work routes, with provenance retained in the source-linked material. <!-- END HUMANIZED RELATIONSHIPS 2026-09-11 --> ## Source route [[articles/2026 Annual Report on Brain-Computer Interfaces|2026 Annual Report on Brain-Computer Interfaces]] · [[collections/Neurotech|Neurotech]] ## Related Work in the Corpus <!-- BEGIN HUMANIZED CORPUS ROUTES 2026-09-11 --> - In [[articles/2026 Annual Report on Brain-Computer Interfaces|2026 Annual Report on Brain-Computer Interfaces]], **Neuralink: Operational Clinical Program and Regulatory Trajectory** provides the narrative context for **Brad (Neuralink participant)**: As of late 2025, Neuralink Corporation has transitioned from speculative R&D to an operational clinical program with regulator-visible outcomes. <!-- END HUMANIZED CORPUS ROUTES 2026-09-11 -->